Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology ...